Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
02/04/16
20160033931 
 End member, rotary body unit and photoreceptor drum unit patent thumbnailnew patent End member, rotary body unit and photoreceptor drum unit
An end member is mounted on an end of a cylindrical rotary body. The end member includes a cylindrical-shaped body and a shaft connecting portion protruding from one end side of the body.
Mitsubishi Chemical Corporation


02/04/16
20160033531 
 Method and compositions for detecting binding to the pregnane x receptor patent thumbnailnew patent Method and compositions for detecting binding to the pregnane x receptor
In one aspect, the invention relates to compounds useful as fluorescence assay probes, methods of making same, and methods of using same to assay ligand binding interactions with pxr. In various aspects, the invention pertains to compositions comprising a polypeptide comprising a pregnane x receptor polypeptide, or a ligand binding fragment polypeptide thereof; and a molecule comprising a bodipy residue and a vinca alkaloid residue.
St. Jude Children's Research Hospital


02/04/16
20160033523 
 Pharmacokinetic animal model patent thumbnailnew patent Pharmacokinetic animal model
The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for hsa binding to the fcrn receptor in said animal. In the non-primate animal species, the binding affinity of wild type hsa to the native fcrn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native fcrn.
University Of Oslo


02/04/16
20160033478 
 Hemokinin-1 receptor and hemokinin-1-derived peptide patent thumbnailnew patent Hemokinin-1 receptor and hemokinin-1-derived peptide
The present invention provides a peptide having antagonist activity against sp, pain control activity, anti-inflammation activity, and anti-pruritic activity. The present invention further provides a method for searching for a therapeutic agent for pain, a therapeutic agent for inflammation, and a therapeutic agent for pruritus using g protein coupled receptor (gpr) 83, which is an hk-1 specific receptor..
University Of Miyazaki


02/04/16
20160033424 
 Motion-based radiograph interlock systems, structures, and processes patent thumbnailnew patent Motion-based radiograph interlock systems, structures, and processes
A motion-based interlock apparatus, system, and method prevent an x-ray source in an x-ray machine from activating if the current relative motion between the x-ray source and an image receptor would compromise the quality of the resulting plain radiograph. The system activates the interlock based on either or both of the velocity and acceleration of the tubehead, as measured by instrumentation corresponding to any of the tubehead, the extension arm, or off board the x-ray machine.
Applied Minds, Llc


02/04/16
20160033413 
 Methods and devices for xerogel based sensors patent thumbnailnew patent Methods and devices for xerogel based sensors
Chemical sensors today are deployed in massive volumes across multiple industries and yet at the same time they are subject to substantial research and development effort to establish new, faster, lower cost, more accurate, more sensitive chemical sensors. Such sensors and sensor arrays are being exploited across chemistry, biology, clinical biology, environmental science in civilian and military markets.
m. according to embodiments of the invention electronic excitation/read circuits for phase based luminophore sensors are presented that are compatible with single cmos chip implementation and monolithic integration of the optical excitation/detection elements.


02/04/16
20160032894 
 System and  optimal operation of wind farms patent thumbnailnew patent System and optimal operation of wind farms
A method implemented using at least one processor module includes receiving a plurality of operational parameters corresponding to a plurality of wind turbines and obtaining a plurality of source sound power values corresponding to the plurality of wind turbines. The method further includes obtaining a receptor sound pressure value corresponding to a receptor location and estimating an attenuation model based on the plurality of source sound power values, and the receptor sound pressure value.
General Electric Company


02/04/16
20160032291 
 Cd7 receptor aptamers patent thumbnailnew patent Cd7 receptor aptamers
Nucleic acid aptamers which bind specifically to or are internalised into cells expressing a cd7 cell-surface receptor are disclosed. The aptamers comprise a nucleic acid molecule having a sequence which is at least 80% identical to 5′-gg-gagacaagaauaagcaug-r1-uucgacaggaggcucacaacagnynz-3′ (seq id no: 3).
University Of The Witwatersrand Johannesburg


02/04/16
20160032259 
 Glycosylated vegf decoy receptor fusion protein patent thumbnailnew patent Glycosylated vegf decoy receptor fusion protein
The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding vegf polypeptide and placenta growth factor (pigf) polypeptide comprising a nucleotide sequence encoding a vegfr1 component.. .
Korea Advanced Institute Of Science And Technology (kaist)


02/04/16
20160032244 
 Method of inducing cellular differentiation using the notch3 receptor intracellular domain patent thumbnailnew patent Method of inducing cellular differentiation using the notch3 receptor intracellular domain
The present invention relates to the intracellular domain of notch3 that can activate signaling and initiate transcription, thereby initiating cellular differentiation in general, and neuronal differentiation in particular. The present invention includes the use of polynucleotide sequences that code, entirely or partially, for the intracellular domain of notch3, for the purpose of inducing cellular differentiation.

02/04/16
20160032018 
new patent

Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa


The present invention concerns the use of immunoglobulins of igg1 type, and more generally of ligands of the cd32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.. .
Stallergenes Sa


02/04/16
20160031999 
new patent

Il-11r binding proteins


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (il-11) receptor alpha (il-11rα) and uses thereof, e.g., in therapy.. .
45 Poplar Road


02/04/16
20160031998 
new patent

Antibodies against g-csfr and uses thereof


The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.. .
Csl Limited


02/04/16
20160031996 
new patent

Anti il-3r alpha agents and uses thereof


The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor α.. .
Csl Limited


02/04/16
20160031994 
new patent

Il3ralpha antibody conjugates and uses thereof


The present invention provides antibodies that bind to the il-3 receptor alpha subunit alpha (il3rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an il3rα-expressing cell population, the methods comprising contacting a population of il3rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to il3rα.
Stemline Therapeutics, Inc.


02/04/16
20160031993 
new patent

Compositions and methods for increasing muscle growth


This disclosure is in the field of anti-activin receptor iib (actriib) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse..
Novartis Ag


02/04/16
20160031989 
new patent

Methods for promoting reinnervation of auditory hair cells


This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting repulsive guidance molecule a (rgma), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin.. .
Massachusetts Eye & Ear Infirmary


02/04/16
20160031967 
new patent

Polypeptides


The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal fc receptor (in the following referred to as fcrn), and provides an fcrn binding polypeptide comprising the sequence ex2x3x4ax6x7 eirwlpnl x16x17x18qrx21 afix25x26lx28x29 (seq id no: 1075). The present disclosure also relates to the use of such an fcrn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent..
Affibody Ab


02/04/16
20160031961 
new patent

Methods and compositions using kloto-fgf fusion polypeptides


The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The klotho fusion polypeptides of the invention include at least a klotho protein or an active fragment thereof.
Novartis Ag


02/04/16
20160031942 
new patent

Rhamm binding peptides


The present invention provides for peptides that bind to receptor for hyaluronic acid mediated motility (rhamm) molecules. More specifically, provided are peptides capable of specifically binding rhamm molecules and capable of binding rhamm with substantially high affinity.
The London Health Sciences Centre Research Inc.


02/04/16
20160031937 
new patent

Neural regeneration peptides and uses therefor


This invention relates to neural regeneration peptides (nrps), including nrp-2945, nrp-2983 and nnz-4921, as well as the receptors that have been newly identified as interacting with these nrps, such as cxcr4 in collaboration with ccr3. The invention further relates to methods of using these nrps and its respective chemokine receptors, as well as compositions comprising such components..
Curonz Holdings Company Limited


02/04/16
20160031908 
new patent

Chemokine receptor antagonists and methods of use thereof


Or physiologically acceptable salt thereof.. .

02/04/16
20160031885 
new patent

Organic compounds


The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-ht2a receptor, serotonin transporter (sert) and/or pathways involving dopamine d2 receptor signaling systems.. .
Intra-cellular Therapies, Inc.


02/04/16
20160031853 
new patent

2-halo-5-alkynyl-pyridyl nicotinic ligands


Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including alzheimer's disease, parkinson's disease, dyskinesias, tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia..
Georgetown University


02/04/16
20160031844 
new patent

Kappa opioid receptor compounds


The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal in need of such treatment a compound of formula i as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, alzheimer's disease, anxiety and addiction, the method comprising administering to a mammal, including a human, in need of such treatment a compound of formula i as described above.. .

02/04/16
20160031817 
new patent

3-piperidone compounds and their use as neurokinin-1 (nk1) receptor antagonists


The invention relates to 3-piperidone compounds, and in particular, to (2s)-phenyl-3-piperidone and its synthesis method. Use of the thus-synthesized 3-piperidone compounds as potent neurokinin-1 (nk1) receptor antagonists is also provided..
Nanyang Technological University


02/04/16
20160031811 
new patent

Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions


Wherein l1, l2, l3, r1, r4, r5, and r6 are as defined in the specification. Compounds of formula (i) are ep4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders.

02/04/16
20160031797 
new patent

Estrogen receptor ligands and methods of use thereof


The present invention relates to a novel class of nuclear receptor binding agents (nrbas). The nrba compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease..
Gtx, Inc.


02/04/16
20160030572 
new patent

Liquid formulations


Disclosed is a concentrate for dilution comprising a s1p receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow..
Novartis Ag


02/04/16
20160030521 
new patent

Therapeutic agents comprising elastin-like peptides


The present invention provides therapeutic agents and compositions comprising elastin-like peptides (elps) and therapeutic proteins. In some embodiments, the therapeutic protein is a glp-1 receptor agonist, insulin, or factor vii/viia, including functional analogs.
Duke University


02/04/16
20160030490 
new patent

Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells


Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof.
Ocata Therapeutics, Inc.


02/04/16
20160030478 
new patent

Materials and methods to enhance hematopoietic stem cells engraftment procedures


This disclosure is directed to the methods of enhancing hematopoietic stem cells (hspc) and progenitor cell (hspc) engraftment procedure. Treatment in vivo of a hspc donor with compounds that reduce pge2 biosynthesis or pge2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as amd3100 and g-csf, increases the circulation of available hspcs.
Indiana University Research And Technology Corp.


02/04/16
20160030474 
new patent

Brain, spinal and nerve injury treatment


A treatment for brain, spinal and nerve injury comprising use of a substance p receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance p receptor antagonist and a magnesium compound..
Eustralis Pharmaceuticals Limited


02/04/16
20160030456 
new patent

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


02/04/16
20160030448 
new patent

Uses for 4, 17ß-dihydroxyandrost-4-ene-3-one


The present invention relates to novel uses of 4,17β-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor.. .
Mabel Gmbh


02/04/16
20160030443 
new patent

Methods and compositions for modulating regulatory t cell function


Pharmaceutical compositions comprising a compound selected from the group consisting of compound nos. 1, 2, 3, 4, 5, 6, 7, 13, 22, 23, 24 and 25, as described in table 1, and a pharmaceutically acceptable excipient.

02/04/16
20160030439 
new patent

Methods for the treatment of autoimmune diseases


The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


02/04/16
20160030430 
new patent

Tetrahydropyrazolopyrimidine compounds


Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis. .
Eisai R&d Management Co., Ltd.


02/04/16
20160030418 
new patent

Method for decreasing low density lipid protein


The present invention further relates to a composition for treating bipolar ii disorder, which comprises valproic acid and at least one agent selected from the group of dextromethorphan and memantine, wherein the dose of dextromethorphan or memantine is a low dose not sufficient to work as a n-methyl-d-aspartate (nmda) receptor antagonist.. .

02/04/16
20160030416 
new patent

Methods of treating b2-bradykinin receptor mediated angioedema


Methods of treating b2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the treatment of b2-bradykinin receptor mediated angioedema.
Shire Human Genetic Therapies, Inc.


02/04/16
20160030415 
new patent

Treatment and prophylaxis of kidney diseases


A method for treatment and/or prophylaxis of kidney diseases of non-inflammatory etiology in mammals is described herein. The method comprises administering hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and angiotensin converting enzyme inhibitors.
Ipca Laboratories Limited


02/04/16
20160030397 
new patent

Compositions and methods of using (r)-pramipexole


Pharmaceutical compositions of (r)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, comt inhibitors, moa inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (ampa) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type b (moab) inhibitors, multi-target agents, kinase inhibitors, bcl inducers, histone deacetylase (hdac) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.. .
Knopp Biosciences Llc


02/04/16
20160030393 
new patent

Novel compounds as opioid receptor modulators


The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.. .

02/04/16
20160030334 
new patent

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof


Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.


02/04/16
20160029960 
new patent

Systems and methods for neurological traffic and/or receptor functional evaluation and/or modification


Systems and methods for controlled sympathectomy procedures for neuromodulation are disclosed. A system for controlled micro ablation procedures is disclosed.
Autonomix Medical, Inc.


02/04/16
20160029853 
new patent

Level entry shower system


Providing an easy to install shower tray and drain assembly. The tray comprises a stepped upper surface and a receptor having at least one step for receiving the drain assembly.

01/28/16
20160027995 

Method for producing a multilayer electromechanical transducer


The invention relates to a process for the production of at least one multilayer electromechanical transducer (44), comprising provision of at least one dielectric elastomer foil (10, 16, 22, 30, 46), application of at least one electrode layer (12, 18, 20, 24, 26, 28, 42) to at least one first part (16.1, 16.4, 22.1) of the elastomer foil (10, 16, 22, 30, 46) in an application step, arrangement of the elastomer foil (10, 16, 22, 30, 46) on a receptor area (4) of a folding apparatus (2), where the folding apparatus (2) has a first plate (2.1) and a second plate (2.2), fixing of the elastomer foil (10, 16, 22, 30, 46) on the receptor area (4), and folding of the first part (16.1, 16.4, 22.1) of the elastomer foil (10, 16, 22, 30, 46) onto another part (16.2, 16.3, 22.3) of the elastomer foil (10, 16, 22, 30, 46) in a folding step via folding of the first plate (2.1) in relation to the second plate (2.2) in such a way that the electrode layer (12, 18, 20, 24, 26, 28, 42) is arranged between the first part (16.1, 16.4, 22.1) of the elastomer foil (10, 16, 22, 30, 46) and the second part (16.2, 16.3, 22.3) of the elastomer foil (10, 16, 22, 30, 46).. .
Hochschule Ostwestfalen Lippe


01/28/16
20160025746 

Methods of screening compounds that can modulate nr2f6 by displacement of a reference ligand


The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor nr2f6 by measuring the ability of a test compound to occupy the active site of nr2f6, in the presence of a reference compound.. .
Regen Biopharma, Inc


01/28/16
20160025734 

Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate


The disclosure provides methods to facilitate the diagnosis of prostate cancer. In particular, the methods disclosed herein can be used to distinguish prostate cancer from benign prostatic hyperplasia.
The Brigham And Women's Hospital, Inc.


01/28/16
20160024498 

Methods for increasing efficacy of lipid formulated sirna


This invention relates to methods for increasing the efficiency of sirna administrations via pre-administration of an agent that lowers ldl receptor levels.. .
Tekmira Pharmaceuticals Corporation


01/28/16
20160024493 

Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set


Compositions and methods are disclosed for uniquely tagging each rearranged gene segment that encodes a t cell receptor (tcr) and/or an immunoglobulin (ig), in a dna (or mrna or cdna reverse transcribed therefrom) sample from lymphoid cells. These and related embodiments permit accurate, high throughput quantification of distinct tcr and/or ig encoding sequences.
Adaptive Biotechnologies Corporation


01/28/16
20160024483 

Method of treating eye disease using glycosylated vegf decoy receptor fusion protein


The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding vegf polypeptide and placenta growth factor (pigf) polypeptide comprising a nucleotide sequence encoding a vegfr1 component.. .
Seoul National University Bundang Hospital


01/28/16
20160024470 

Methods and materials for the generation of regulatory t cells


Methods are disclosed for the generation of immunosuppressive regulatory t cells. The methods can include contacting a population of cd4+cd25− t cells with a t cell receptor (tcr)/cd3 activator, a tcr co-stimulator activator, and rapamycin.
Life Technologies As


01/28/16
20160024226 

Hybrid immunoglobulin containing non-peptidyl linkage


The present invention provides compounds producing compounds having the structure (i). Wherein a is a first polypeptide component of the compound; wherein c is a second polypeptide component of the compound, which polypeptide component comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an fc domain of an antibody; (ii) bind to an fc receptor, and (iii) have at their n-terminus a sequence selected from the group consisting of a cysteine, selenocysteine, cp, cpxcp (where x=p, r, or s), cdkthtcppcp, cvecppcp, ccvecppcp and cdtpppcprcp, wherein b is a chemical structure linking a and c; wherein the dashed line between b and c represents a peptidyl linkage; wherein the solid line between a and b represents a nonpeptidyl linkage comprising the structure (ii)..

01/28/16
20160024213 

Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases


The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (mmr) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics.
Vrije Universiteit Brussel


01/28/16
20160024211 

Methods of modulating immune function


Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of b7-h7 to b7-hrcr, or the binding of b7-h2 to either icos, cd28, or ctla-4.
The Johns Hopkins University


01/28/16
20160024210 

Anti-h7cr antibodies


Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, h7cr, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University


01/28/16
20160024202 

Human antibody specific for interleukin-1alpha


Fully human monoclonal abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for il-1α and (ii) a constant region that is effective at both activating the complement system though c1q binding and binding to several different fc receptors.. .
Xbiotech, Inc.


01/28/16
20160024199 

Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii


Disclosed herein are human monoclonal antibodies that specifically bind both igf-i and igf-ii with picomolar affinity and potently inhibit the igf-ir signal transduction function. These antibodies are active in both an igg and a scfv format.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


01/28/16
20160024189 

Flavivirus neutralizing antibodies and methods of use thereof


The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mab11 which recognizes west nile virus e protein and is cross-reactive with members of the flavivirus family, including denge virus.
Dana-farber Cancer Institute, Inc.


01/28/16
20160024177 

Novel epitope for switching to th1 cell and use thereof


The present invention relates to a novel epitope that converts t cell to type 1 helper t (th1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th1 cell and a method for converting t cell to th1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody..

01/28/16
20160024176 

Ox40l fusion proteins and uses thereof


The disclosure provides ox40l huigg4 fusion polypeptide subunits comprising a human igg4 fc domain, a trimerization domain, and the receptor binding domain of ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer..
Medimmune, Llc


01/28/16
20160024174 

Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen


Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a ny-eso-1 antigen. Included are recombinant t cell receptors (tcrs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including cd4+ t cells, cd8+ t cells, natural killer t cells, γδ t cells, and progenitor cells, such as haematopoietic stem cells.
Health Research, Inc.


01/28/16
20160024172 

Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof


The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (rap) and compositions thereof, methods of generating such variants and methods of using such receptor-selective rap variant compositions for therapeutic purposes.. .
Raptor Pharmaceuticals Inc.


01/28/16
20160024169 

Insulin-incretin conjugates


Disclosed herein are insulin agonist peptides conjugated to incretins wherein the insulin/incretin conjugate has agonist activity at both the insulin receptor and the corresponding incretin receptor. Insulin is a proven therapy for the treatment of juvenile-onset diabetes and later-stage adult-onset diabetes.
Indiana University Research And Technology Corporation


01/28/16
20160024167 

Methods and compositions based on diphtheria toxin-interleukin-3 conjugates


The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (dt-il3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the dt-il3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3.
Scott & White Memorial Hospital


01/28/16
20160024163 

Modulation of angiogenesis and related conditions using inhibitors of g-protein-coupled receptor kinase interacting protein-1 (git1)


The present invention is directed to methods and compositions comprising g-protein-coupled receptor kinase interacting protein-1 (git1) inhibitors that are suitable for inhibiting angiogenesis in a subject and treating related conditions.. .
University Of Rochester


01/28/16
20160024135 

Adenosine receptor activation reagent and the uses of thereof


The present invention relates to application of n(6)-(2-hydroxyethyl)-adenosine (hea) and its derivatives as an adenosine a1 receptor agonist in preparation of drug or food, the hea and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney..
Zhejiang Subtropical Crops Research Institute


01/28/16
20160024086 

Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof


As well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of retinoic acid receptor-related orphan receptor regulated diseases and disorders..

01/28/16
20160024083 

Compounds and methods for treating cancers


Provided are carbazole and carbazole-like compounds (e.g., pyridoindole and pyrrolodipyridine) compounds, that can be used to selectively kill cancer cells, specifically androgen-receptor expressing prostate cancer cells. Also provided is a method of treating ar-positive prostate cancer in a subject diagnosed with or suspected of having ar positive or negative cancer, comprising administering an effective amount of a carbazole and carbazole-like compound to said subject..
Health Research, Inc.


01/28/16
20160024064 

Azetidine amide derivatives as orexin receptor antagonists


The present invention relates to azetidine amide derivatives derivatives of formula (i) wherein rings a1 a2 and a3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (i), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.. .
Actelion Pharmaceuticals Ltd


01/28/16
20160024057 

Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof


As well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of retinoic acid receptor-related orphan receptor regulated diseases and disorders..

01/28/16
20160024056 

Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof


As well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of retinoic acid receptor-related orphan receptor regulated diseases and disorders..

01/28/16
20160024052 

Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof


As well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of retinoic acid receptor-related orphan receptor regulated diseases and disorders..

01/28/16
20160024038 

Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release


Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including alzheimer's disease, parkinson's disease, huntington's disease, fronto-temporal dementia, pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, down syndrome, and aging-related cns disorders..
Rosalind Franklin University Of Medicine And Science


01/28/16
20160024031 

Heterocyclic compounds useful in the treatment of disease


Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (rs)-3-cyclopropyl-2-{4-[3-methyl-4((r)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (r)-1-(4′-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid..
Epigen Biosciences, Inc.


01/28/16
20160024023 

Low molecular weight thyroid stimulating hormone receptor (tshr) agonists


Disclosed are oxo-hydroquinazolines that are useful as selective tshr agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder..
Forschungsverbund Berlin E.v.


01/28/16
20160024014 

5ht2c receptor modulators


Which act as 5ht2c receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity..

01/28/16
20160024009 

Novel sulfonamide trpa1 receptor antagonists


The invention discloses compounds of formula (i). The compounds of formula (i) are trpa1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of trpa1 receptors..
Ario Pharma Limited


01/28/16
20160024006 

Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions


And therapeutic methods of treatment with compounds of formula (i), wherein l1, l2, l4, r1, r4, r5, r6, and s are as defined in the specification. Compounds of formula (i) are ep4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders..

01/28/16
20160023990 

Non-peptide bdnf neurotrophin mimetics


Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a trkb receptor molecule..
Pharmatrophix, Inc.


01/28/16
20160022841 

Method for augmenting vision in persons suffering from photoreceptor cell degeneration


The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject.
The General Hospital Corporation


01/28/16
20160022836 

Mir-204 and mir-211 and uses thereof


The present invention relates to at least one agent capable of increasing the level of one or more mirna in a cell or cells of a subject, said mirna comprising the sequence uucccuu, for use in the treatment and/or prevention of a retinal dystrophy, in particular characterized by photoreceptor degeneration, relative pharmaceutical compositions, nucleic acids, vectors and host cells.. .
Fondazione Telethon


01/28/16
20160022814 

Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer


The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a listeria based strain that expresses prostate-tissue specific antigen (psa), and the use of the combination therapies for the treatment of prostate cancer.. .
Merck Sharpe And Dohme Corp.


01/28/16
20160022779 

Activators of cxcr3 for the treatment of angiopathies of the eye


The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the c-terminal α-helix of ip-10.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/28/16
20160022776 

Trail receptor agonists for treatment of fibrotic disease


Pro-apoptotic agents such as ligands and agonists of agonistic trail receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (hscs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (pscs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells.
Theraly Pharmaceuticals, Inc.


01/28/16
20160022772 

Cytokine receptors as targets for hypertension therapy and methods of use


The present disclosure provides methods of treating or ameliorating hypertension in a subject comprising administering a therapeutically effective amount of an il-1 receptor antagonist.. .
Duke University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/28/16
20160022752 

Plant extracts with anti-diabetic and other useful activities


This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling.
Hmi Medical Innovations, Llc


01/28/16
20160022710 

Prenatal and lactation supplements to enhance central nervous system development of offspring


Disclosed are prenatal and lactation supplements for pregnant women and lactating women, which include a combination of rrr-alpha-tocopherol, docosahexaenoic acid (dha), trans-lutein, phospholipids, and at least one nuclear receptor activating ligand other than rrr-alpha-tocopherol, dha, and trans-lutein. The supplements may enhance central nervous system development in a fetus or breast-feeding newborn infant..
Abbott Laboratories


01/28/16
20160022678 

Therapeutic compositions containing macitentan


The invention relates to a product containing the compound of formula (i) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (ip) agonist properties, or a pharmaceutically acceptable salt thereof.. .
Actelion Pharmaceuticals Ltd


01/28/16
20160022677 

Solid forms of an epidermal growth factor receptor kinase inhibitor


The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of egfr kinases and which exhibit desirable characteristics for the same.. .
Celgene Avilomics Research, Inc.


01/28/16
20160022670 

Benzamides


Wherein w1, w2, r1 to r7, r6, x and y have the meaning according to the claims, are positive allosteric modulators of the fsh receptor, and can be employed, inter alia, for the treatment of fertility disorders.. .

01/28/16
20160022658 

Pharmaceutical compositions and their methods of use


The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.. .
Abbvie Inc.


01/28/16
20160022653 

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations


The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.

01/28/16
20160022652 

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations


The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.

01/28/16
20160022642 

Compounds useful for promoting protein degradation and methods using same


The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the clogp of the compound is equal to or higher than 1.5.
Yale University


01/28/16
20160022638 

Methods of treatment associated with the granulocyte colony-stimulating factor receptor


Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (gcfr) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a gcfr modulator to a subject in need thereof..
Ligand Pharmaceuticals Incorporated


01/28/16
20160022635 

Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer


Described herein are methods of decreasing the proliferation of prostate cancer cells in a mammalian subject by administering to a subject in need thereof a composition comprising an avpr antagonist in amount effective to decrease proliferation of the cancer cells. Also provided are methods of inducing prostate cancer cell death (or decreasing invasion migration of the prostate cancer cells) in a mammalian subject by administering to a subject in need thereof a composition comprising an avpr antagonist..
University Of Miami


01/28/16
20160022607 

Uses for idebenone and related benzoquinones in metabolic disorders and other ppar alpha/gamma related diseases and conditions


The present invention relates to the use of a 1,4-benzoquinone derived compound for the treatment of a disease or condition that is associated with peroxisome proliferator activated receptor (ppar) activity in a mammal.. .
Indanio Bioscience Inc.


01/28/16
20160022185 

A biosensor device to target analytes in situ, in vivo, and/or in real time, and methods of making and using the same


A biosensor device for the real-time detection of a target analyte includes a receptor component operatively connected to a transducer component which is adapted to interpret and transmit a detectable signal. The receptor component includes a sensing element capable of detecting and binding to at least one target analyte, and a self-assembled monolayer (sam) layer.
The University Of Toledo






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3852

5082

0 - 1 - 112